377 related articles for article (PubMed ID: 18950436)
1. Titration with oxymorphone extended release to achieve effective long-term pain relief and improve tolerability in opioid-naive patients with moderate to severe pain.
Rauck R; Ma T; Kerwin R; Ahdieh H
Pain Med; 2008 Oct; 9(7):777-85. PubMed ID: 18950436
[TBL] [Abstract][Full Text] [Related]
2. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
3. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
Hale ME; Ahdieh H; Ma T; Rauck R;
J Pain; 2007 Feb; 8(2):175-84. PubMed ID: 17145204
[TBL] [Abstract][Full Text] [Related]
7. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial.
Matsumoto AK; Babul N; Ahdieh H
Pain Med; 2005; 6(5):357-66. PubMed ID: 16266356
[TBL] [Abstract][Full Text] [Related]
8. The pain quality response profile of oxymorphone extended release in the treatment of low back pain.
Gould EM; Jensen MP; Victor TW; Gammaitoni AR; White RE; Galer BS
Clin J Pain; 2009 Feb; 25(2):116-22. PubMed ID: 19333156
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis.
Peniston JH; Xiang Q; Gould EM
Curr Med Res Opin; 2010 Aug; 26(8):1861-71. PubMed ID: 20521870
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study.
Hale ME; Dvergsten C; Gimbel J
J Pain; 2005 Jan; 6(1):21-8. PubMed ID: 15629415
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty.
Ahdieh H; Ma T; Babul N; Lee D
J Clin Pharmacol; 2004 Jul; 44(7):767-76. PubMed ID: 15199081
[TBL] [Abstract][Full Text] [Related]
12. A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain.
Katz N; Rauck R; Ahdieh H; Ma T; Gerritsen van der Hoop R; Kerwin R; Podolsky G
Curr Med Res Opin; 2007 Jan; 23(1):117-28. PubMed ID: 17257473
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
14. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
16. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
17. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study.
Gabrail NY; Dvergsten C; Ahdieh H
Curr Med Res Opin; 2004 Jun; 20(6):911-8. PubMed ID: 15200750
[TBL] [Abstract][Full Text] [Related]
18. Oral oxymorphone for pain management.
Chamberlin KW; Cottle M; Neville R; Tan J
Ann Pharmacother; 2007 Jul; 41(7):1144-52. PubMed ID: 17595308
[TBL] [Abstract][Full Text] [Related]
19. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial.
Gimbel JS; Walker D; Ma T; Ahdieh H
Arch Phys Med Rehabil; 2005 Dec; 86(12):2284-9. PubMed ID: 16344024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]